Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.
about
Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis."No evidence of disease activity" - is it an appropriate surrogate in multiple sclerosis?The effect of disease modifying therapies on CD62L expression in multiple sclerosis
P2860
Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.
@en
type
label
Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.
@en
prefLabel
Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.
@en
P2093
P2860
P1433
P1476
Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.
@en
P2093
Florian Deisenhammer
Harald Hegen
Michael Auer
P2860
P2888
P304
P356
10.1007/S40265-016-0639-3
P577
2016-09-21T00:00:00Z
P6179
1043843400